A citation-based method for searching scientific literature

P George, R J McCrimmon. Diabet Med 2013
Times Cited: 29







List of co-cited articles
152 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Dipeptidyl peptidase 4 inhibitor sitagliptin maintains β-cell function in patients with recent-onset latent autoimmune diabetes in adults: one year prospective study.
Yunjuan Zhao, Lin Yang, Yufei Xiang, Lingjiao Liu, Gan Huang, Zhaofeng Long, Xia Li, R David Leslie, Xiangbing Wang, Zhiguang Zhou. J Clin Endocrinol Metab 2014
69
6

Effects of Sotagliflozin Added to Insulin in Patients with Type 1 Diabetes.
Satish K Garg, Robert R Henry, Phillip Banks, John B Buse, Melanie J Davies, Gregory R Fulcher, Paolo Pozzilli, Diane Gesty-Palmer, Pablo Lapuerta, Rafael Simó,[...]. N Engl J Med 2017
182
6



Dipeptidyl-peptidase-IV inhibition augments postprandial lipid mobilization and oxidation in type 2 diabetic patients.
Michael Boschmann, Stefan Engeli, Kerstin Dobberstein, Petra Budziarek, Anke Strauss, Jana Boehnke, Fred C G J Sweep, Friedrich C Luft, Yanling He, James E Foley,[...]. J Clin Endocrinol Metab 2009
79
3

Efficacy and safety of sitagliptin when added to insulin therapy in patients with type 2 diabetes.
T Vilsbøll, J Rosenstock, H Yki-Järvinen, W T Cefalu, Y Chen, E Luo, B Musser, P J Andryuk, Y Ling, K D Kaufman,[...]. Diabetes Obes Metab 2010
225
3

DPP-4 inhibitors and lipids: systematic review and meta-analysis.
Matteo Monami, Caterina Lamanna, Carla Maria Desideri, Edoardo Mannucci. Adv Ther 2012
128
3

Further improvement in postprandial glucose control with addition of exenatide or sitagliptin to combination therapy with insulin glargine and metformin: a proof-of-concept study.
Sabine Arnolds, Sibylle Dellweg, Janina Clair, Marie-Paule Dain, Michael A Nauck, Klaus Rave, Christoph Kapitza. Diabetes Care 2010
126
3

Safety and tolerability of sitagliptin in clinical studies: a pooled analysis of data from 10,246 patients with type 2 diabetes.
Debora Williams-Herman, Samuel S Engel, Elizabeth Round, Jeremy Johnson, Gregory T Golm, Hua Guo, Bret J Musser, Michael J Davies, Keith D Kaufman, Barry J Goldstein. BMC Endocr Disord 2010
183
3


Effect of metformin on fibrinolytic parameters in insulin-treated, type 2 diabetic patients.
H Gin, M F Roudaut, V Vergnot, L Baillet, V Rigalleau. Diabetes Metab 2003
7
14

Poor achievement of guidelines-recommended targets in type 2 diabetes: findings from a contemporary prospective cohort study.
M F B Braga, A Casanova, H Teoh, H C Gerstein, D H Fitchett, G Honos, P A McFarlane, E Ur, J-F Yale, A Langer,[...]. Int J Clin Pract 2012
32
3

Combination therapies of DPP4 inhibitors and GLP1 analogues with insulin in type 2 diabetic patients: a systematic review.
Evangelos C Rizos, Evangelia E Ntzani, Nikolaos Papanas, Vasilis Tsimihodimos, Zoi Mitrogianni, Efstratios Maltezos, Moses S Elisaf. Curr Vasc Pharmacol 2013
9
11

Effect of vildagliptin on glucagon concentration during meals in patients with type 1 diabetes.
J E Foley, M Ligueros-Saylan, Y-L He, J J Holst, C F Deacon, B E Dunning, A Leone-Jones, T Yu, D E Kelley. Horm Metab Res 2008
32
3


Dipeptidyl peptidase-4 inhibitors for the treatment of type 2 diabetes mellitus.
Joshua J Neumiller, Lindy Wood, R Keith Campbell. Pharmacotherapy 2010
93
3

Time for testing incretin therapies in early type 1 diabetes?
Emanuele Bosi. J Clin Endocrinol Metab 2010
24
4


Discordance between HbA1c and fructosamine: evidence for a glycosylation gap and its relation to diabetic nephropathy.
Robert M Cohen, Yancey R Holmes, Thomas C Chenier, Clinton H Joiner. Diabetes Care 2003
131
3


Update on incretin hormones.
Liza K Phillips, Johannes B Prins. Ann N Y Acad Sci 2011
77
3

Prevalence of achievement of A1c, blood pressure, and cholesterol (ABC) goal in veterans with diabetes.
Scott Martin Vouri, Robert F Shaw, Nancee V Waterbury, Jason A Egge, Bruce Alexander. J Manag Care Pharm 2011
37
3

Increasing duration of type 1 diabetes perturbs the strength-structure relationship and increases brittleness of bone.
Jeffry S Nyman, Jesse L Even, Chan-Hee Jo, Erik G Herbert, Matthew R Murry, Gael E Cockrell, Elizabeth C Wahl, R Clay Bunn, Charles K Lumpkin, John L Fowlkes,[...]. Bone 2011
66
3


Advanced glycation end-products attenuate human mesenchymal stem cells and prevent cognate differentiation into adipose tissue, cartilage, and bone.
Shinichiro Kume, Seiya Kato, Sho-ichi Yamagishi, Yosuke Inagaki, Seiji Ueda, Nobuyuki Arima, Takahiro Okawa, Masamichi Kojiro, Kensei Nagata. J Bone Miner Res 2005
161
3

Type 2 diabetic mice demonstrate slender long bones with increased fragility secondary to increased osteoclastogenesis.
Yuki Kawashima, J Christopher Fritton, Shoshana Yakar, Sol Epstein, Mitchell B Schaffler, Karl J Jepsen, Derek LeRoith. Bone 2009
48
3


Rosiglitazone causes bone loss in mice by suppressing osteoblast differentiation and bone formation.
A Afshan Ali, Robert S Weinstein, Scott A Stewart, A Michael Parfitt, Stavros C Manolagas, Robert L Jilka. Endocrinology 2005
311
3

Diabetes induced changes in rat mesenchymal stem cells.
Alexandra Stolzing, Donna Sellers, Owen Llewelyn, Andy Scutt. Cells Tissues Organs 2010
87
3


Hypoglycaemic effects of antidiabetic drugs in streptozotocin-nicotinamide-induced mildly diabetic and streptozotocin-induced severely diabetic rats.
Atsuo Tahara, Akiko Matsuyama-Yokono, Ryosuke Nakano, Yuka Someya, Masayuki Shibasaki. Basic Clin Pharmacol Toxicol 2008
33
3


A role for advanced glycation end products in diminished bone healing in type 1 diabetes.
Ronaldo B Santana, Lei Xu, Hermik Babakhanlou Chase, Salomon Amar, Dana T Graves, Philip C Trackman. Diabetes 2003
139
3

Advanced glycation end-products (AGEs) induce concerted changes in the osteoblastic expression of their receptor RAGE and in the activation of extracellular signal-regulated kinases (ERK).
Ana M Cortizo, María G Lettieri, Daniel A Barrio, Natalia Mercer, Susana B Etcheverry, Antonio D McCarthy. Mol Cell Biochem 2003
57
3

Prospective study of diabetes and risk of hip fracture: the Nurses' Health Study.
Mohsen Janghorbani, Diane Feskanich, Walter C Willett, Frank Hu. Diabetes Care 2006
201
3

The biology of osteocytes.
Giolanta Kogianni, Brendon S Noble. Curr Osteoporos Rep 2007
36
3

Metformin reverts deleterious effects of advanced glycation end-products (AGEs) on osteoblastic cells.
L Schurman, A D McCarthy, C Sedlinsky, M V Gangoiti, V Arnol, L Bruzzone, A M Cortizo. Exp Clin Endocrinol Diabetes 2008
52
3



Regulation of advanced glycation end product (AGE) receptors and apoptosis by AGEs in osteoblast-like cells.
Natalia Mercer, Hafiz Ahmed, Susana B Etcheverry, Gerardo R Vasta, Ana Maria Cortizo. Mol Cell Biochem 2007
52
3

Metformin: intrinsic vasculoprotective properties.
N F Wiernsperger. Diabetes Technol Ther 2000
50
3


Bone is a target for the antidiabetic compound rosiglitazone.
S O Rzonca, L J Suva, D Gaddy, D C Montague, B Lecka-Czernik. Endocrinology 2004
318
3

Effect of metformin on bone marrow progenitor cell differentiation: in vivo and in vitro studies.
M Silvina Molinuevo, Leon Schurman, Antonio D McCarthy, Ana M Cortizo, María J Tolosa, M Virginia Gangoiti, Veronica Arnol, Claudia Sedlinsky. J Bone Miner Res 2010
113
3

Advanced glycation end products affect growth and function of osteoblasts.
S Franke, C Rüster, J Pester, G Hofmann, P Oelzner, G Wolf. Clin Exp Rheumatol 2011
48
3

Delayed bone regeneration and low bone mass in a rat model of insulin-resistant type 2 diabetes mellitus is due to impaired osteoblast function.
Christine Hamann, Claudia Goettsch, Jan Mettelsiefen, Veit Henkenjohann, Martina Rauner, Ute Hempel, Ricardo Bernhardt, Nadja Fratzl-Zelman, Paul Roschger, Stefan Rammelt,[...]. Am J Physiol Endocrinol Metab 2011
80
3

Increased bone adiposity and peroxisomal proliferator-activated receptor-gamma2 expression in type I diabetic mice.
Sergiu Botolin, Marie-Claude Faugere, Hartmut Malluche, Michael Orth, Ron Meyer, Laura R McCabe. Endocrinology 2005
156
3

Non-enzymatic glycosylation of a type I collagen matrix: effects on osteoblastic development and oxidative stress.
A D McCarthy, S B Etcheverry, L Bruzzone, G Lettieri, D A Barrio, A M Cortizo. BMC Cell Biol 2001
78
3




Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.